Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.270317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Betül Altunay und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Immunotherapy, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
PSMA-targeted radiopharmaceutical therapy (RPT) is a standard treatment for metastatic castration-resistant prostate cancer (PCa), exploiting PSMA overexpression to deliver cytotoxic radiation. Treatment with the β-emitter [177Lu]Lu-PSMA-617, approved in 2022, has been associated with prolonged progression-free and overall survival in patients with PCa. However, resistance and heterogeneous patient responses limit its efficacy. Although immunotherapy is effective in several malignancies, PCa's immunosuppressive microenvironment often reduces its impact. Combining targeted RPT with immune checkpoint inhibitors, particularly programmed cell death protein 1 and programmed cell death ligand 1 inhibitors, may enhance antitumor responses. This review explores the rationale behind this combination, evaluates preclinical and clinical evidence, and discusses future directions for integrating immune checkpoint blockade with targeted RPT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany.
- Institute for Experimental Molecular Imaging, University Hospital Aachen, Aachen, Germany.
- Center for Integrated Oncology, University Hospital Aachen, Aachen, Germany.
- Department of Urology and Pediatric Urology, University Hospital Aachen, Aachen, Germany; and.
- Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
- Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany; sluetje@ukaachen.de.
Zitieren
APA
Altunay, B., Schäfer, L., Morgenroth, A., Peña, Q., Lammers, T., Saar, M., Mottaghy, F. M., & Lütje, S. (2025). Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270317
Vancouver
Altunay B, Schäfer L, Morgenroth A, Peña Q, Lammers T, Saar M, et al. Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270317
BibTeX
@article{Altunay2025,
author = {Altunay, Betül and Schäfer, Laura and Morgenroth, Agnieszka and Peña, Quim and Lammers, Twan and Saar, Matthias and Mottaghy, Felix M and Lütje, Susanne},
title = {Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.270317}
}
EUVIMED